Compare
SBC Medical Group Holdings Inc vs LifeMD, Inc. vs Airsculpt Technologies, Inc. vs Starling Oncology, Inc.
| Latest fiscal year | SBC Medical Group Holdings Inc SBC | LifeMD, Inc. LFMD | Airsculpt Technologies, Inc. AIRS | Starling Oncology, Inc. STLN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $173.61M | $194.06M | $151.82M | $502.73M |
| Revenue growth (YoY) | -15.5% | +25.3% | -15.8% | +27.8% |
| Gross margin | 73.3% | 85.7% | n/a | n/a |
| Operating margin | 38.9% | -4.0% | -7.6% | -7.2% |
| Net margin | 29.4% | 7.4% | -7.7% | -12.1% |
| Net income | $50.99M | $14.35M | -$11.67M | -$60.61M |
| EPS (Diluted) | $0.50 | $0.25 | -$0.19 | -$0.54 |
| Operating cash flow | $24.67M | $8.28M | $3.10M | -$24.59M |
| Free cash flow | $23.27M | $6.41M | $692.0K | -$27.79M |
| Cash & equivalents | $163.77M | n/a | $8.45M | n/a |
| Total assets | $380.45M | $70.41M | $187.30M | $164.66M |
| Total liabilities | $117.14M | $47.25M | $99.59M | $180.38M |
| Shareholders' equity | $248.28M | $23.16M | $87.71M | -$15.72M |
| Return on year-end equity | 20.5% | 62.0% | -13.3% | n/a |
| Shares outstanding | 102.58M | 46.66M | 64.46M | 98.86M |
Revenue, most recent five fiscal years
| Fiscal year | SBC Medical Group Holdings Inc | LifeMD, Inc. | Airsculpt Technologies, Inc. | Starling Oncology, Inc. |
|---|---|---|---|---|
| Latest | $173.61M Ended 2025-12-31 | $194.06M Ended 2025-12-31 | $151.82M Ended 2025-12-31 | $502.73M Ended 2025-12-31 |
| 1 year earlier | $205.42M Ended 2024-12-31 | $154.82M Ended 2024-12-31 | $180.35M Ended 2024-12-31 | $393.41M Ended 2024-12-31 |
| 2 years earlier | $193.54M Ended 2023-12-31 | $152.55M Ended 2023-12-31 | $195.92M Ended 2023-12-31 | $324.24M Ended 2023-12-31 |
| 3 years earlier | n/a | $119.03M Ended 2022-12-31 | $168.79M Ended 2022-12-31 | $252.48M Ended 2022-12-31 |
| 4 years earlier | n/a | $92.88M Ended 2021-12-31 | $133.31M Ended 2021-12-31 | $203.00M Ended 2021-12-31 |